Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease

Table 3 Distribution of liver histopathological findings according to general non-alcoholic fatty liver disease scoring system for rodent models, n (%)

Variable1	Control (n = 8)	HCC (n = 7)	RIF (n = 7)
No MASLD	8 (100)	0 (0.0)	0 (0.0)
MASLD	0 (0.0)	0 (0.0)	0 (0.0)
MASH	0 (0.0)	7 (100)	7 (100)

¹Variables described as frequency (%).

HCC: Hepatocellular carcinoma; MASLD: Metabolic-dysfunction associated steatotic liver disease; MASH: Metabolic-dysfunction associated steatohepatitis; RIF: Rifaximin.